Literature DB >> 4031382

Clonidine-suppression test in epinephrine secreting pheochromocytoma: report of a case.

A G Dupont, P Vanderniepen, E Gerlo, G Somers, L Vanhaelst, P in't Veld, W Gepts, R Sacre, R O Six.   

Abstract

A patient is described in whom the diagnosis of pheochromocytoma was suspected on clinical grounds. He had normal urinary and plasma norepinephrine levels, with normal suppression of plasma norepinephrine by clonidine. However, plasma and urinary epinephrine levels were above normal, and plasma epinephrine was not suppressed but increased by clonidine. Selective venous sampling showed marked unilateral adrenal epinephrine excess. A large epinephrine secreting pheochromocytoma was surgically removed. This case suggests that, in pheochromocytomas releasing predominantly epinephrine, normal norepinephrine release from axon terminals of sympathetic postganglionic neurons is maintained and is suppressed by clonidine administration. It further reaffirms the value of plasma epinephrine estimations in the diagnosis of pheochromocytoma and indicates that normal suppression of plasma norepinephrine by clonidine does not preclude the presence of a predominantly epinephrine secreting tumor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031382     DOI: 10.1007/BF03350673

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  14 in total

1.  Adrenaline and noradrenaline producing tumors of the adrenal medulla and sympathetic nerves.

Authors:  M GOODALL; C STONE
Journal:  Ann Surg       Date:  1960-03       Impact factor: 12.969

2.  Catecholamines in the localization of pheochromocytoma.

Authors:  J R CROUT; A SJOERDSMA
Journal:  Circulation       Date:  1960-10       Impact factor: 29.690

3.  Studies on catecholamines, renin and aldosterone following Catapresan (2-(2,6-dichlor-phenylamine)-2-imidazoline hydrochloride) in hypertensive patients.

Authors:  B Hökfelt; H Hedeland; J F Dymling
Journal:  Eur J Pharmacol       Date:  1970       Impact factor: 4.432

4.  Diagnosis of small phaeochromocytomas.

Authors:  M J Brown; P J Lewis; C T Dollery
Journal:  Lancet       Date:  1980-05-31       Impact factor: 79.321

5.  A paroxysmally secreting phaeochromocytoma: biochemical and clinical aspects.

Authors:  H Hörtnagl; D Magometschnigg; H Lochs; W Druml
Journal:  Klin Wochenschr       Date:  1983-06-15

6.  Activation of the central pathway of the baroreceptor reflex, a possible mechanism of the hypotensive action of clonidine.

Authors:  G Haeusler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

7.  Circulating catecholamine levels in human and experimental hypertension.

Authors:  J de Champlain; L Farley; D Cousineau; M R van Ameringen
Journal:  Circ Res       Date:  1976-02       Impact factor: 17.367

8.  Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications.

Authors:  E L Bravo; R C Tarazi; R W Gifford; B H Stewart
Journal:  N Engl J Med       Date:  1979-09-27       Impact factor: 91.245

9.  Catecholamine suppression testing in patient with phaechromocytoma and normal plasma catecholamine levels.

Authors:  P D Levinson; B K Lance; A A Kowarski; B P Hamilton
Journal:  Lancet       Date:  1983-05-28       Impact factor: 79.321

10.  Role of venous sampling in locating a phaeochromocytoma.

Authors:  D J Allison; M J Brown; D H Jones; J B Timmis
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-02
View more
  3 in total

Review 1.  Diagnostic problems in pheochromocytoma.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

2.  Evaluation of the clonidine-suppression test in the diagnosis of pheochromocytoma.

Authors:  G Plewe; U Krause; U Cordes; J Beyer
Journal:  Klin Wochenschr       Date:  1988-09-01

3.  Usefulness of basal catecholamine plasma levels and clonidine suppression test in the diagnosis of pheochromocytoma.

Authors:  M Mannelli; M L De Feo; M Maggi; C Pupilli; G Opocher; T Valenza; E Baldi; M Serio
Journal:  J Endocrinol Invest       Date:  1987-08       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.